ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,247.79
-0.41%
Dow Jones
39,112.16
-0.76%
Gold vs US Dollar
2,316.915
-0.16%
Brent Oil
84.665
0.57%
Bitcoin
61,575.96
-0.37%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Aadi Bioscience Inc (AADI)

  7. Aadi Bioscience Inc (AADI) News

Aadi Bioscience (AADI)

Aadi Bioscience Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AADI
DateTimeSourceHeadlineSymbolCompany
14/06/202421:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
14/06/202421:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
14/06/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
14/06/202421:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
14/06/202421:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
12/06/202421:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AADIAadi Bioscience Inc
05/06/202421:25Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
03/06/202417:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AADIAadi Bioscience Inc
29/05/202421:05PR Newswire (US)Aadi Bioscience to Participate in the Jefferies Healthcare ConferenceNASDAQ:AADIAadi Bioscience Inc
23/05/202422:30PR Newswire (US)Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:AADIAadi Bioscience Inc
08/05/202421:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AADIAadi Bioscience Inc
08/05/202413:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AADIAadi Bioscience Inc
08/05/202413:00PR Newswire (US)Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
01/05/202413:01PR Newswire (US)Aadi Bioscience to Report First Quarter 2024 Results and Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
09/04/202413:00PR Newswire (US)Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingNASDAQ:AADIAadi Bioscience Inc
17/03/202412:00PR Newswire (US)Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)NASDAQ:AADIAadi Bioscience Inc
13/03/202412:00PR Newswire (US)Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
06/03/202413:00PR Newswire (US)Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate UpdateNASDAQ:AADIAadi Bioscience Inc
05/03/202421:30PR Newswire (US)Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024NASDAQ:AADIAadi Bioscience Inc
05/03/202400:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
05/03/202400:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
05/03/202400:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
01/03/202421:08PR Newswire (US)Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComaNASDAQ:AADIAadi Bioscience Inc
01/03/202418:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AADIAadi Bioscience Inc
26/02/202421:05PR Newswire (US)Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:AADIAadi Bioscience Inc
12/02/202422:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AADIAadi Bioscience Inc
12/02/202422:16Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AADIAadi Bioscience Inc
02/02/202422:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AADIAadi Bioscience Inc
26/01/202421:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers SymposiumNASDAQ:AADIAadi Bioscience Inc
19/01/202421:05PR Newswire (US)Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers SymposiumNASDAQ:AADIAadi Bioscience Inc
 Showing the most relevant articles for your search:NASDAQ:AADI

Your Recent History

TG
A184SD
Microsoft
COIN
EUROCUST
Euro Coin
LSE
SXLY
Spdr $ Cons Dis
NYSE
BRSP
BrightSpire Capital
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved